21,136 Shares in Insulet Corporation $PODD Bought by Mirae Asset Global Investments Co. Ltd.

by · The Markets Daily

Mirae Asset Global Investments Co. Ltd. bought a new position in Insulet Corporation (NASDAQ:PODD – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,136 shares of the medical instruments supplier’s stock, valued at approximately $2,758,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its position in Insulet by 6.0% in the third quarter. ProShare Advisors LLC now owns 20,802 shares of the medical instruments supplier’s stock worth $2,714,000 after purchasing an additional 1,185 shares during the last quarter. Vise Technologies Inc. boosted its position in shares of Insulet by 52.9% in the third quarter. Vise Technologies Inc. now owns 5,503 shares of the medical instruments supplier’s stock worth $718,000 after purchasing an additional 1,903 shares during the period. International Assets Investment Management LLC boosted its position in shares of Insulet by 61,543.8% in the third quarter. International Assets Investment Management LLC now owns 45,000 shares of the medical instruments supplier’s stock worth $5,871,000 after purchasing an additional 44,927 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Insulet by 144.7% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,356 shares of the medical instruments supplier’s stock worth $3,308,000 after purchasing an additional 14,996 shares in the last quarter. Finally, Parcion Private Wealth LLC purchased a new stake in shares of Insulet in the third quarter worth $300,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

  • Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
  • Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
  • Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
  • Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Analyst Upgrades and Downgrades

PODD has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. Raymond James Financial reissued an “outperform” rating and set a $180.00 price objective on shares of Insulet in a report on Thursday, August 6th. TD Cowen restated a “hold” rating on shares of Insulet in a research report on Wednesday. Royal Bank Of Canada raised their price objective on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, UBS Group lifted their target price on Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday. Twelve investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Hold” and an average price target of $185.38.

View Our Latest Research Report on PODD

Insulet Trading Down 6.2%

Shares of PODD traded down $9.61 during midday trading on Friday, hitting $146.51. The stock had a trading volume of 1,567,721 shares, compared to its average volume of 1,380,594. The stock’s 50 day moving average is $141.97 and its 200 day moving average is $176.65. The firm has a market cap of $10.16 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.24 EPS. As a group, analysts forecast that Insulet Corporation will post 6.75 EPS for the current fiscal year.

About Insulet

(Free Report)

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

Further Reading